/
ORKA
$93.72+$1.23 (+1.33%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.5B
60M shares
52-week range
$10.97 – $95.38
98% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$68.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $22.0K | $89.0K | $93.0K | $91.0K | $114.0K | $111.0K | $27.0K | $83.0K |
| Gross profit | −$22.0K | −$89.0K | −$93.0K | −$91.0K | −$114.0K | −$111.0K | −$27.0K | −$83.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.2M | $1.8M | $5.0M | $13.8M | $4.5M | $1.0M | $75.1M | $100.6M |
| Operating income | −$8.1M | −$5.8M | −$9.8M | −$19.3M | −$9.8M | −$7.3M | −$88.1M | −$122.1M |
| EBITDA | −$7.9M | −$5.6M | −$9.6M | −$19.2M | −$9.8M | −$5.2M | −$82.2M | −$105.3M |
| Net income | −$7.9M | −$5.5M | −$9.7M | −$19.3M | −$9.9M | −$5.3M | −$83.7M | −$105.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -123.73 | -49.79 | -8.40 | -16.68 | -8.27 | -4.44 | -4.99 | -2.31 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.11 | $-2.41–$-1.92 | 7 |
| 2027 | $0 | $-2.49 | $-2.95–$-2.29 | 7 |
| 2028 | $0 | $-3.24 | $-5.66–$-1.81 | 7 |
| 2029 | $0 | $-4.26 | $-4.26–$-4.26 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.90
Price
$93.72
Implied downside
-99%
Peer comparison
Oruka Therapeutics, Inc. Common Stock
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
www.orukatx.com- Employees
- 68
- IPO / List date
- Sep 3, 2024
- HQ
- MENLO PARK, CA
Held by traders on TradeandTell
No one on the platform currently holds ORKA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 13,900 | $155.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ORKA yet.
